2010
DOI: 10.1586/erv.10.137
|View full text |Cite
|
Sign up to set email alerts
|

Oncolytic vaccinia virus: a silver bullet?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
9
0

Year Published

2013
2013
2021
2021

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(9 citation statements)
references
References 23 publications
0
9
0
Order By: Relevance
“…VACV, which was used as a live-attenuated vaccine for the eradication of smallpox, has been extensively studied as the prototypic representative of the poxvirus family. VACV has also been developed as an oncolytic agent and is currently being tested in various clinical trials as an oncolytic virotherapeutic for the treatment of end-stage cancers, such as liver cancer or cancer that has metastasized to the liver (2)(3)(4)(5)(6)(7). A second poxvirus with demonstrated oncolytic potential is myxoma virus (MYXV), which belongs to the genus Leporipoxvirus (8)(9)(10).…”
mentioning
confidence: 99%
“…VACV, which was used as a live-attenuated vaccine for the eradication of smallpox, has been extensively studied as the prototypic representative of the poxvirus family. VACV has also been developed as an oncolytic agent and is currently being tested in various clinical trials as an oncolytic virotherapeutic for the treatment of end-stage cancers, such as liver cancer or cancer that has metastasized to the liver (2)(3)(4)(5)(6)(7). A second poxvirus with demonstrated oncolytic potential is myxoma virus (MYXV), which belongs to the genus Leporipoxvirus (8)(9)(10).…”
mentioning
confidence: 99%
“…127,128 JX-594 (tk gene deleted, GM-CSF expressing VV Wyeth; Pexa-Vec) 129 has been evaluated in phase I-II clinical trials for patients with metastatic melanoma, (primary) liver tumors, lung, colorectal and various other solid cancer types. GLV-1h68 (GL-ONC1) is currently being investigated in several phase I clinical trials.…”
Section: Family Poxviridae: Vaccinia Virus (Vv)mentioning
confidence: 99%
“…vvDD is vaccinia growth factor deficient, acting in concert with tk deletion to limit viral infection to tumor cells [16]. JX-594 is a vector expressing GMCSF to enhance the induced immune response [16].…”
Section: Oncolytic Virusesmentioning
confidence: 99%
“…vvDD is vaccinia growth factor deficient, acting in concert with tk deletion to limit viral infection to tumor cells [16]. JX-594 is a vector expressing GMCSF to enhance the induced immune response [16]. The GL-ONC1 vector expresses β-galactosidase and β-glucuronidase, each of which may play a role in stimulation of the host immune response [16].…”
Section: Oncolytic Virusesmentioning
confidence: 99%
See 1 more Smart Citation